Skip to content
Sign in

HRTS · NASDAQ · ETF

Tema Heart & Health ETF (HRTS) Price, Holdings & Fees

$1,072.95+0.85%+$9.02End-of-day price as of Oct 9, 2026

Tema Heart & Health ETF (HRTS) closed at $1,072.95 on Oct 9, 2026, up 0.85% from the previous close of $1,063.93.

Share price, past year

1Y +17.88%

52-week range $871.42 – $1,072.95. Daily closing prices.
Monthly closing prices
Last closing price of each month
DateClose
Oct 9, 2026$1,072.95
Sep 30, 2026$1,031.62
Aug 31, 2026$923.62
Jul 31, 2026$876.84
Jun 30, 2026$888.41
May 29, 2026$900.39
Apr 30, 2026$879.58
Mar 31, 2026$886.92
Feb 27, 2026$929.46
Jan 30, 2026$959.14
Dec 31, 2025$948.19
Nov 28, 2025$984.04
Oct 31, 2025$952.87

Key statistics

Expense ratio
0.75%
as of Jun 30, 2026
Net assets
$51.9M
as of May 31, 2026
Holdings
45
as of May 31, 2026
52-week range
$871.42 – $1,072.95

Tema Heart & Health ETF's expense ratio is 0.75%: $75.00 a year on $10,000 invested.

Holdings

Tema Heart & Health ETF held 45 investments worth $51.92M as of May 31, 2026. Its largest holding was Eli Lilly & Co, at 11.52% of the fund.

Tema Heart & Health ETF largest holdings by share of net assets
#Holding% of fundValue
1Eli Lilly & CoLLY11.52%$5.98M
2UnitedHealth Group IncUNH5.24%$2.72M
3Novo Nordisk A/S5.24%$2.72M
4Roche Holding AGRHHBY4.50%$2.33M
5Merck & Co IncMRK4.27%$2.22M
6AstraZeneca PLCAZN4.00%$2.08M
7Thermo Fisher Scientific IncTMO3.97%$2.06M
8Johnson & JohnsonJNJ3.59%$1.86M
9Gilead Sciences IncGILD3.43%$1.78M
10Novartis AG3.38%$1.76M
11Revolution Medicines IncRVMD3.33%$1.73M
12Vertex Pharmaceuticals IncVRTX2.93%$1.52M
13Danaher CorpDHR2.66%$1.38M
14Abbott LaboratoriesABT2.61%$1.35M
15Bridgebio Pharma IncBBIO2.59%$1.35M
16Cytokinetics IncCYTK2.52%$1.31M
17AbbVie IncABBV2.40%$1.24M
18Bristol-Myers Squibb CoBMY2.09%$1.08M
19Teva Pharmaceutical IndustriesTEVA2.06%$1.07M
20Dexcom IncDXCM1.92%$996.37K
21Amgen IncAMGN1.91%$992.18K
22Medtronic PLCMDT1.88%$974.51K
23Edwards Lifesciences CorpEW1.75%$906.90K
24McKesson CorpMCK1.71%$887.96K
25Regeneron Pharmaceuticals IncREGN1.67%$865.61K

Top 25 of 45 holdings, as of May 31, 2026. Percentages are of the fund's net assets.

What the fund owns

Tema Heart & Health ETF holdings by asset type
Asset type% of fund
Stocks99.16%
Cash and short-term investments0.72%
Tema Heart & Health ETF holdings by country, largest 8
Country% of fund
United States74.86%
Switzerland7.88%
Denmark6.99%
United Kingdom4.00%
Israel2.06%
Ireland1.88%
Japan1.33%
Canada0.88%

Shares of net assets from the fund's N-PORT report. Funds that borrow can add up to more than 100%, with borrowing (such as repurchase agreements) shown as a negative share.

Monthly total returns

Over the 3 months to May 31, 2026, Tema Heart & Health ETF's total return was −4.90%, as reported to the SEC.

Tema Heart & Health ETF monthly total returns
MonthTotal return
May 31, 2026+2.13%
Apr 30, 2026+0.23%
Mar 31, 2026−7.10%

The fund's own total returns as reported to the SEC (N-PORT), including reinvested distributions. Not the sample prices above.

Fund profile

Name
Tema Heart & Health ETF
Ticker
HRTS
Exchange
NASDAQ
Fund type
ETF
Trust
Tema ETF Trust
SEC series ID
S000081541
SEC CIK
0001944285
Fractional shares
No

Recent SEC filings

Shareholder reports and prospectuses are filed by Tema ETF Trust, the trust behind Tema Heart & Health ETF, and cover all of its funds.

Frequently asked questions

What is HRTS's price?

Tema Heart & Health ETF (HRTS) closed at $1,072.95 on Oct 9, 2026, up 0.85% from the previous close of $1,063.93.

What is HRTS's expense ratio?

Tema Heart & Health ETF's expense ratio is 0.75%: $75.00 a year on $10,000 invested.

What does HRTS hold?

Tema Heart & Health ETF held 45 investments worth $51.92M as of May 31, 2026. Its largest holding was Eli Lilly & Co, at 11.52% of the fund. Its five largest holdings were Eli Lilly & Co, UnitedHealth Group Inc, Novo Nordisk A/S, Roche Holding AG, Merck & Co Inc.

How has HRTS performed?

Over the 3 months to May 31, 2026, Tema Heart & Health ETF's total return was −4.90%, as reported to the SEC.

Sources and methodology

Holdings, net assets and monthly returns come from the fund's N-PORT filing with the SEC, as of May 31, 2026 (filed Jul 29, 2026). The expense ratio is from the fund's prospectus or shareholder report, as of Jun 30, 2026. Prices are generated sample data for development. Data sources and disclosures